Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Y-Mabs Therapeutics Inc
(NQ:
YMAB
)
11.88
+1.11 (+10.31%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Y-Mabs Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement
November 22, 2024
Via
Benzinga
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
November 18, 2024
Via
Benzinga
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook
November 07, 2024
Via
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Navigating 8 Analyst Ratings For Y-mAbs Therapeutics
September 09, 2024
Via
Benzinga
Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
August 13, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
March 06, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Outlook For Y-mAbs Therapeutics
February 28, 2024
Via
Benzinga
Earnings Preview For Y-mAbs Therapeutics
November 10, 2023
Via
Benzinga
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
August 12, 2024
The company didn't quite meet expectations for either trailing results or full-year guidance.
Via
The Motley Fool
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
August 12, 2024
YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
August 12, 2024
Via
Benzinga
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
July 22, 2024
From
Pomerantz LLP
Via
GlobeNewswire
4 Analysts Have This to Say About Y-mAbs Therapeutics
August 14, 2023
Via
Benzinga
Analyst Expectations for Y-mAbs Therapeutics's Future
July 25, 2023
Via
Benzinga
Where Y-mAbs Therapeutics Stands With Analysts
June 07, 2023
Via
Benzinga
MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
July 02, 2024
Via
Benzinga
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 07, 2024
YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 01, 2024
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.
Via
Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
March 01, 2024
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 29, 2024
Via
Benzinga
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
February 16, 2024
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.
Via
Investor's Business Daily
Micro Marvel - Y-Mabs Therapeutics
February 13, 2024
Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year.
Via
Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
January 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 12, 2024
Via
Benzinga
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.